Number of the records: 1
Beyond glycan barriers: non-cognate ligands and protein mimicry approaches to elicit broadly neutralizing antibodies for HIV-1
- 1.
SYSNO ASEP 0597669 Document Type J - Journal Article R&D Document Type Journal Article Subsidiary J Článek ve WOS Title Beyond glycan barriers: non-cognate ligands and protein mimicry approaches to elicit broadly neutralizing antibodies for HIV-1 Author(s) Walimbwa, S. I. (CZ)
Malý, Petr (BTO-N) RID, ORCID
Kafkova, L. R. (CZ)
Raška, M. (CZ)Number of authors 4 Article number 83 Source Title Journal of Biomedical Science. - : BioMed Central - ISSN 1021-7770
Roč. 31, č. 1 (2024)Number of pages 16 s. Language eng - English Country GB - United Kingdom Keywords HIV-1 vaccine ; Glycans ; Broadly neutralizing antibodies Subject RIV FP - Other Medical Disciplines OECD category Pathology Method of publishing Open access Institutional support BTO-N - RVO:86652036 UT WOS 001295899000001 EID SCOPUS 85201673672 DOI https://doi.org/10.1186/s12929-024-01073-y Annotation Human immunodeficiency virus type 1 (HIV-1) vaccine immunogens capable of inducing broadly neutralizing antibodies (bNAbs) remain obscure. HIV-1 evades immune responses through enormous diversity and hides its conserved vulnerable epitopes on the envelope glycoprotein (Env) by displaying an extensive immunodominant glycan shield. In elite HIV-1 viremic controllers, glycan-dependent bNAbs targeting conserved Env epitopes have been isolated and are utilized as vaccine design templates. However, immunological tolerance mechanisms limit the development of these antibodies in the general population. The well characterized bNAbs monoclonal variants frequently exhibit extensive levels of somatic hypermutation, a long third heavy chain complementary determining region, or a short third light chain complementarity determining region, and some exhibit poly-reactivity to autoantigens. This review elaborates on the obstacles to engaging and manipulating the Env glycoprotein as an effective immunogen and describes an alternative reverse vaccinology approach to develop a novel category of bNAb-epitope-derived non-cognate immunogens for HIV-1 vaccine design. Workplace Institute of Biotechnology Contact Monika Kopřivová, Monika.Koprivova@ibt.cas.cz, Tel.: 325 873 700 Year of Publishing 2025 Electronic address https://jbiomedsci.biomedcentral.com/articles/10.1186/s12929-024-01073-y
Number of the records: 1